Trident Lifeline Limited has submitted to the BSE unaudited financial result (Standalone and consolidated) for the quarter ended June,2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.8 pts less than Nifty Microcap 250 and 6.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Trident Lifeline submitted unaudited results for Q1 FY26 (quarter ended June 30, 2025). Standalone total income rose to ₹1,935.48 lakhs from ₹1,520.96 lakhs in Q1 FY25, a growth of about 27%, while standalone net profit grew to ₹347.59 lakhs from ₹301.26 lakhs (~15% growth). On a consolidated basis, total income jumped to ₹2,495.90 lakhs from ₹1,830.46 lakhs (~36% growth), with consolidated net profit at ₹306.28 lakhs versus ₹229.26 lakhs (~34% growth). The statutory auditor (A Bafna & Associates) issued an unqualified limited review report with no qualifications, emphasis of matter, or going concern flag. The board also approved the appointment of M/s. Amareliya & Associates as Secretarial Auditor for a first term of 5 years (FY 2025-26 to FY 2029-30), subject to shareholder approval.
Strong top-line growth on both standalone and consolidated bases, with healthy consolidated profit growth, signals improving business momentum. The clean (unqualified) auditor review removes any near-term governance overhang, though standalone PAT growth is modest. Net positive read for shareholders.